Familial nonmedullary thyroid carcinoma—clinical relevance and prognosis. A European multicenter study

Hillenbrand, Andreas; Varhaug, J E; Brauckhoff, Michael; Pandev, Rumen; Haufe, Sabine; Dotzenrath, Cornelia; Köberle, Roswitha; Hoffmann, Rainer; Klein, Günther; Kadmon, Martina; Negele, Thomas; Hagieva, Tatjana; Henne‐Bruns, Doris; Luster, Markus; Weber, Theresia

doi:10.1007/s00423-010-0696-0

Cited by 42 publications

(34 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The low prevalence of FNMTC, together with small sampling series and short follow-up studies, has limited consistent information on patient survival as well. Some studies have reported distinct clinical behaviours (3,16,17,18,19,20,21), but others have claimed that there are no differences between the two entities (1,22,23,24,25). Our present data seem to support the latter view, as we did not observe, overall, statistical differences in clinicopathological features, DNA ploidy status and outcome measures between familial PTC (whole series) and sporadic PTC.…”

Section: Discussionsupporting

confidence: 73%

“…Although some studies have reported a less favourable prognosis for FNMTC (3,16,17,18,19,20,21), others did not verify this (1,22,23,24,25), and therefore, the biological and clinical behaviour of this familial disease, as compared with the much more frequent sporadic forms, remains a matter of controversy. Furthermore, data on molecular biomarkers, e.g.…”

Section: Introductionmentioning

confidence: 98%

“…Familial non-medullary thyroid cancer (FNMTC) accounts for w5% of all thyroid carcinomas of follicular cell origin (1,2,3,4). A vast majority of patients with FNMTC present papillary thyroid carcinoma (PTC), although benign thyroid lesions, such as multinodular goitre, are also commonly found in members of these families (2,4,5).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour

Pinto

Silva²,

Henrique

et al. 2014

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Familial non-medullary thyroid cancer has been proposed as an aggressive clinical entity. Our aim in this study is to investigate potential distinguishing features as well as the biological and clinical aggressiveness of familial vs sporadic papillary thyroid carcinoma (PTC). We assessed clinicopathological characteristics, outcome measures and DNA ploidy. Design: A matched-case comparative study. Methods: A series of patients with familial PTC (nZ107) and two subgroups, one with three or more affected elements (nZ32) and another including index cases only (nZ61), were compared with patients with sporadic PTC (nZ107), matched by age, gender, pTNM disease extension and approximate follow-up duration. Histological variant, extrathyroidal extension, vascular invasion, tumour multifocality and bilateral growth were evaluated. Ploidy pattern was analysed in available samples by DNA flow cytometry. The probabilities of disease-free survival (DFS) and overall survival (OS) were estimated according to the Kaplan-Meier (K-M) method. Results: No patient with familial PTC died of disease during follow-up (median, 72 months), contrarily to five patients (4.7%) (PZ0.06) with sporadic PTC (median, 90 months). There was a significantly higher tumour multifocality in familial PTC (index cases subgroup) vs sporadic PTC (PZ0.035), and a trend, in the familial PTC cohort with three or more affected elements, to show extrathyroidal extension (PZ0.054) more frequently. No difference was observed in DNA ploidy status. The K-M analyses showed no significant differences between both entities in relation to DFS or OS. Conclusion: Apart from multifocality, familial PTC appears to have similar clinical/prognostic behaviour when compared with sporadic forms of the disease.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour

Pinto

Silva²,

Henrique

et al. 2014

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Nevertheless, based on the current available evidence, it may be rational that screening individuals with relatives affected by thyroid cancer commence at an earlier age. However, there is no strict age cutoff at which screening should begin; some authors (17,22,23) recommend that screening should commence at the age of 18-20 years, or 5-10 years earlier than the youngest age of diagnosis with the family, which remains to be further elucidated. As given in Table 2, most of subgroup analyses did not show significant difference to the overall conclusion.…”

Section: Discussionmentioning

confidence: 99%

“…A number of researchers have found that FNMTC has more aggressive biological behaviors, characterized by a higher incidence of multifocality, extrathyroidal invasion, bilateral disease, and lymph node metastases, which lead to a higher recurrence rate and decreased disease-free survival (DFS) (11,12,13,14,15,16,17). Therefore, some of them recommended more aggressive initial treatment for patients with FNMTC, including total thyroidectomy (TT) and concomitant prophylactic central compartment node dissection (14,17). However, certain other studies did not confirm the difference in biological behaviors between FNMTC and SNMTC (18,19,20,21).…”

Section: Introductionmentioning

confidence: 99%

ENDOCRINE TUMOURS: Familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis

Wang

Cheng

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: There is controversy as to whether familial nonmedullary thyroid carcinoma (FNMTC) is more aggressive than sporadic NMTC (SNMTC). The aim of the study was to evaluate the biological characteristics of patients with FNMTC by a meta-analysis. Methods: Four databases (PubMed, EMBASE, the Cochrane library databases, and the Web of Science) were searched to identify studies published before September, 2014. All original studies that compared clinical characteristics and prognosis of patients with FNMTC and SNMTC were included. The pooled effect sizes of interesting parameters were calculated by odds ratio (OR), standard mean difference (SMD), or hazard ratio (HR). Results: Twelve studies with a total of 12 741 participants were included in this analysis. FNMTC patients had an increased rate of recurrence (ORZ1.72, 95% CI: 1.34 to 2.20) and decreased disease-free survival (DFS) (HRZ1.83, 95% CI: 1.34 to 2.52) in comparison with SNMTC patients. FNMTC possessed more aggressive biological behaviors, characterized by younger age at diagnosis (SMDZK0.91, 95% CI: K1.59 to K0.22), higher risk of multifocal (ORZ1.50, 95% CI: 1.32 to 1.71), bilateral (ORZ1.29, 95% CI: 1.00 to 1.66), extrathyroidal invasion (ORZ1.20, 95% CI: 1.02 to 1.41), and lymph node metastasis (ORZ1.18, 95% CI: 1.01 to 1.38). Conclusion: FNMTC is a more aggressive disease and possesses higher recurrence rate and lower DFS. More attention and careful consideration should be paid regarding the decision about treatment for patients with FNMTC.

show abstract

Familial history of non‐medullary thyroid cancer is an independent prognostic factor for tumor recurrence in younger patients with conventional papillary thyroid carcinoma

Lee

Yoon

et al. 2013

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Familial nonmedullary thyroid carcinoma—clinical relevance and prognosis. A European multicenter study

Cited by 42 publications

References 30 publications

Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour

Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour

ENDOCRINE TUMOURS: Familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis

Familial history of non‐medullary thyroid cancer is an independent prognostic factor for tumor recurrence in younger patients with conventional papillary thyroid carcinoma

Contact Info

Product

Resources

About